Continuing efanesoctocog alfa after earlier trial
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital, Immune system & allergy clinical trials.
This study provides continued access to the clotting factor treatment efanesoctocog alfa for people who have already been getting it in a previous trial. It helps ensure you can keep using the medicine if it is working for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child have completed one of the earlier studies with efanesoctocog alfa (Sobi.BIVV001-001, Sobi.BIVV001-003, LTS16294, or Sobi.BIVV001-004) and are still benefiting from the treatment.
- You do not have a high level of inhibitors (antibodies that stop the medicine from working).
- You are not taking part in any other clinical trial right now.
- You or your parent/legal representative can give permission (informed consent) and will keep a daily diary.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a new factor VIII medicine, efanesoctocog alfa, protects your joints over time. It's for people with moderate or severe hemophilia A who are just starting this treatment.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
This study tests a new preventive treatment (efanesoctocog alfa) for people with hemophilia A who have joint lining thickening. The goal is to see if it helps protect joints.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
This study tests a treatment called Altuviiio for children with severe hemophilia A who have developed inhibitors (antibodies that block factor replacement). The goal is to help the body become tolerant to factor therapy again, preventing bleeding episodes.
This trial tests a new medicine, bometase alfa, to stop bleeding in people with a rare bleeding disorder called acquired hemophilia A. The goal is to control active bleeding episodes safely.
Hear when a new Haemophilia A (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.